Ask around any weight-loss clinic and you will hear a version of the same story. Someone started a GLP-1 injection to lose weight and a few weeks later noticed they had stopped finishing their wine. Not through willpower. The second glass simply stopped appealing.
For a long time these accounts sat in the awkward space between interesting and useless. Doctors heard them constantly. Researchers could not do much with them, because a story is not evidence. That has changed over the past eighteen months, and 2026 in particular has produced the first properly designed trials that put numbers to what patients were describing.
Here is where the science on Mounjaro, alcohol cravings and the wider GLP-1 class actually stands, including the parts that are still unresolved.
What patients report
The pattern described by patients is fairly consistent. Alcohol does not become unpleasant. It becomes uninteresting. People say the pull towards a drink weakens, the pleasure from drinking feels flatter, and the urge to keep going after the first one fades.
That last detail matters more than it sounds. It suggests the effect is landing on motivation and reward rather than on taste or nausea. Someone who felt sick after drinking would avoid alcohol entirely. What people describe instead is indifference, which points to something happening upstream in the brain.
Why the brain might respond this way
GLP-1 is a hormone the gut releases after eating. It tells the pancreas to release insulin and tells the brain you have had enough. Drugs like semaglutide and tirzepatide copy that signal and make it last far longer than the natural version.
The relevant point for alcohol is that GLP-1 receptors are not confined to the gut and pancreas. They also sit in the mesolimbic dopamine system, the circuitry that assigns value to rewarding things. Food is one of those things. So is alcohol. So is nicotine.
When these drugs activate receptors in that system, they appear to dampen the dopamine response that makes a rewarding thing feel worth repeating. In practice, the brain treats a drink as less of an event. Researchers describe this as an on-target consequence of how the drug works, rather than a side effect in the usual sense.
Animal work supports the mechanism directly. A University of Gothenburg team reported in February 2026 that voluntary alcohol consumption fell by more than half in animals treated with tirzepatide, and that the drug also prevented relapse-like drinking. The same team found tirzepatide reduced alcohol’s effect on dopamine, the neurotransmitter behind much of alcohol’s reinforcing pull.
What the research on GLP-1 drugs and alcohol actually found
This is where most coverage goes wrong, because two bodies of evidence have been telling slightly different stories.
The population data looked dramatic.
Studies drawing on large medical record databases have consistently found lower rates of alcohol-related problems among people prescribed GLP-1 medicines. One systematic review pooling six observational studies covering more than 2.7 million people reported a hazard ratio of 0.64 for alcohol-related events, with the effect holding specifically for alcohol use disorder.
Those numbers are eye-catching. They are also the weakest form of evidence here. People prescribed these drugs differ from people who are not in ways that medical records cannot fully capture, and that difference can produce an effect that looks real but is not caused by the medicine.
The early randomised trials were more cautious.
When the same review pooled the randomised controlled trials available at the time, the picture softened considerably. Reductions in alcohol consumption, drinks per drinking day and craving were all statistically non-significant, although semaglutide showed a greater reduction in craving than the other drugs assessed.
That was three small trials, roughly 430 people between them. Not enough to prove much either way, but enough to warn against treating the population data as settled fact.
Then 2026 shifted the balance.
Two trials moved things on.
The first, published in The Lancet on 2 May 2026, is the largest to date. An international team led by Anders Fink-Jensen at Copenhagen University Hospital enrolled 108 people who had both alcohol use disorder and obesity, giving them weekly semaglutide or placebo for 26 weeks, with cognitive behavioural therapy offered to everyone.
Heavy drinking days fell in both groups, but significantly more in the semaglutide group, which also showed larger drops in total monthly consumption, drinks per drinking day, self-reported craving and measures of harmful use. Blood biomarkers for alcohol intake and liver damage declined further in that group too, which matters because biomarkers do not exaggerate the way self-reports can.
The second arrived on 29 July 2026 in the American Journal of Psychiatry. Researchers at CU Anschutz tested oral semaglutide in 50 adults seeking treatment for moderate to severe alcohol use disorder over eight weeks. It reduced heavy drinking days, drinking intensity, craving and alcohol-related consequences but missed its primary endpoint, a laboratory measure of cue-triggered craving.
That miss is worth sitting with. A trial that improves real-world drinking while failing its main laboratory measure is a genuinely mixed result, and honest reporting should say so.
Where Mounjaro fits specifically
Most articles blur semaglutide and tirzepatide together. They are not the same drug, and the evidence behind them is not the same depth.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide, the active ingredient in Mounjaro, acts on both GLP-1 and GIP receptors. Nearly all the human trial evidence on alcohol so far involves semaglutide. The tirzepatide evidence is currently animal work plus record-based analyses.
Eli Lilly is direct about this. The company states that it has not evaluated tirzepatide for alcohol use disorder or alongside alcohol use and that people with a history of alcohol misuse were excluded from its clinical trials.
A randomised trial of tirzepatide in people with both schizophrenia and alcohol use disorder is now recruiting, running 26 weeks with 108 participants. Results are some way off.
So the fair summary for Mounjaro is this: plausible mechanism, strong animal data, no dedicated human trial yet.
What this does not mean
None of this makes any GLP-1 medicine a treatment for a drinking problem. Reducing alcohol intake is not an approved use for Mounjaro or Wegovy anywhere, and nobody should start or continue one in order to drink less.
If drinking is causing problems in your life, the treatments with actual approval behind them are the ones to ask about, alongside talking therapies. It is worth noting that the Lancet trial gave cognitive behavioural therapy to every participant, including the placebo group, and both groups improved. The medicine added to that foundation rather than replacing it.
The trials also studied people who had obesity as well as alcohol use disorder. Whether the effect holds in people at a normal weight is still an open question the researchers themselves flagged.
Drinking alcohol while taking a GLP-1
Separate from cravings, there are practical considerations if you drink while on one of these medicines.
- Side effects stack. Nausea, reflux and stomach upset are common early on, and alcohol can make all three worse.
- Binge patterns are the ones to avoid. Heavy sessions carry the most risk, partly because alcohol and GLP-1 medicines share a link to pancreatitis.
- Dehydration is a real concern. If vomiting or diarrhoea occurs, keep fluids up and contact your prescriber rather than pushing through.
- Alcohol works against weight loss. It adds calories that carry no useful nutrition and tends to loosen restraint around food.
UK guidance remains 14 units a week spread over several days, and many prescribers suggest staying well under that during treatment.
Buying Mounjaro safely in the UK
Interest in these medicines has driven a surge in searches like buy Mounjaro online UK, and that demand has attracted sellers who should not be selling anything.
Mounjaro is a prescription-only medicine in the UK. It cannot legally be supplied without a clinical assessment by a UK-registered prescriber, and no legitimate service will skip that step. Any site offering it without one is operating outside the law.
The risk is not theoretical. In a Drug Safety Update dated 24 February 2026, the MHRA reported that Eli Lilly had identified five falsified versions of the Mounjaro 15mg KwikPen supplied through a Birmingham clinic. Counterfeit pens have previously been found to contain insulin rather than tirzepatide, which is dangerous in a way that is easy to underestimate.
Checks worth making before you order
- The pharmacy displays its GPhC registration number, which you can verify on the register at pharmacyregulation.org
- The site carries the UK distance selling logo, which should link through to the MHRA register of authorised online sellers
- A consultation and medical history review are required before any prescription is issued
- Pricing sits in a normal range. Unusually cheap pens are a warning sign, not a bargain
- The service tells you what is included, since consultation fees, needles, sharps bins and delivery are sometimes charged separately
Buying prescription medicines through social media or messaging apps is illegal and offers no guarantee of authenticity, storage or clinical oversight.
What to watch next
The direction of travel is clear enough. Larger trials are being planned following the CU Anschutz results, and the tirzepatide trial now recruiting will eventually tell us whether the dual-agonist mechanism behaves like semaglutide on this measure.
The questions still open are the ones that determine whether this becomes a treatment or stays an interesting observation: how large the effect is, how long it lasts, whether it works in people without obesity, and what happens when someone stops.
For now, the accurate answer to the question in the title is yes, probably, for some people, more clearly with semaglutide than with tirzepatide, and not yet in a form that makes it a treatment.
Frequently asked questions
Does Mounjaro stop alcohol cravings?
Some people taking it report exactly that. Animal studies support the mechanism, and record-based studies point the same way, but no completed human trial has tested tirzepatide specifically for alcohol cravings. The stronger human evidence involves semaglutide.
Is it safe to drink alcohol on Mounjaro?
There is no formal contraindication, but alcohol can worsen nausea and stomach side effects, affects blood sugar unpredictably, and adds calories that work against weight loss. Heavy or binge drinking is the pattern to avoid. Discuss it with your prescriber.
Can I get a GLP-1 medicine to help me cut down on drinking?
No. This is not an approved use in the UK, and no prescriber should be issuing one for that reason. If drinking is a concern, ask your GP about treatments that are approved for it.
Why do these drugs affect alcohol at all?
They act on receptors in the brain’s reward system, not only in the gut. Alcohol and food share that circuitry, so dampening the reward signal appears to affect both.
How long does the effect take?
Most reports describe changes within the first few weeks, often as the dose increases. It varies considerably between individuals.
This article is for information only and is not medical advice. Mounjaro is a prescription-only medicine in the UK and is not licensed for treating alcohol use disorder. Speak to a GP, pharmacist or registered prescriber about your own circumstances. If you are worried about your drinking, your GP can refer you to local support services.
Sources
- Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. The Lancet, 2 May 2026.
- Schacht JP et al. Oral semaglutide for alcohol use disorder: a randomised clinical trial. American Journal of Psychiatry, 29 July 2026.
- Edvardsson CE et al. Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. eBioMedicine, February 2026.
- Sinha and Ghosal. Effects of GLP-1RAs on alcohol-related outcomes: systematic review and meta-analysis. Addiction Science & Clinical Practice, 2025.
- MHRA Drug Safety Update: falsified Mounjaro KwikPen, 24 February 2026.
- Eli Lilly medical information: tirzepatide and concomitant alcohol use.